Seclidemstat is primarily investigated for its potential therapeutic applications in treating certain types of cancers and neurodegenerative diseases. It functions as a selective inhibitor of lysine-specific demethylase 1 (LSD1), an enzyme involved in the regulation of gene expression. By inhibiting LSD1, seclidemstat may help reactivate tumor suppressor genes and impede cancer cell growth, making it a promising candidate for treating cancers such as Ewing sarcoma and acute myeloid leukemia (AML). Additionally, its role in modulating epigenetic mechanisms has sparked interest in its application for neurodegenerative conditions like Alzheimer’s disease, where abnormal gene expression patterns contribute to disease progression. Clinical trials are ongoing to evaluate its efficacy and safety in these areas.